Topic map

1. Basics & classification - definition, AML vs ALL, WHO/FAB classification
2. Pathogenesis - genetic mutations, cytogenetics, molecular drivers, "two-hit" model
3. Clinical features - presentation from marrow failure and organ infiltration
4. Investigations - CBC/blood film, bone marrow aspirate/biopsy, immunophenotyping (flow cytometry), cytogenetics/FISH, molecular studies (FLT3, NPM1, BCR-ABL etc.), CSF exam for ALL
5. Prognosis - risk stratification (age, cytogenetics, molecular markers, WBC count, MRD status)
6. Treatment - induction, consolidation, CNS prophylaxis (ALL), targeted therapy (e.g., ATRA/APL, FLT3 inhibitors), stem cell transplant, supportive care
7. Monitoring treatment response - MRD assessment, cytogenetic/molecular remission, blood counts, complications monitoring (tumor lysis, infection, cytopenias)

Brief overview

Topic map

1. Basics & classification - definition, AML vs ALL, WHO/FAB classification
2. Pathogenesis - genetic mutations, cytogenetics, molecular drivers, "two-hit" model
3. Clinical features - presentation from marrow failure and organ infiltration
4. Investigations - CBC/blood film, bone marrow aspirate/biopsy, immunophenotyping (flow cytometry), cytogenetics/FISH, molecular studies (FLT3, NPM1, BCR-ABL etc.), CSF exam for ALL
5. Prognosis - risk stratification (age, cytogenetics, molecular markers, WBC count, MRD status)
6. Treatment - induction, consolidation, CNS prophylaxis (ALL), targeted therapy (e.g., ATRA/APL, FLT3 inhibitors), stem cell transplant, supportive care
7. Monitoring treatment response - MRD assessment, cytogenetic/molecular remission, blood counts, complications monitoring (tumor lysis, infection, cytopenias)

Brief overview

Acute Leukemia — Comprehensive Overview

1. Basics

• Acute Myeloid Leukemia (AML) — arises from myeloid precursors; median age at presentation ~65 years; most common acute leukemia in adults (Washington Manual of Medical Therapeutics, p. 3307).
• Acute Lymphoblastic Leukemia (ALL) — arises from lymphoid precursors (B-lineage ~75% of cases, T-lineage ~25%); peak incidence in children age 2-10 years for B-ALL, while T-ALL more often presents in adolescence with mediastinal masses (Robbins & Kumar Basic Pathology, p. 402).
• Acute leukemia of ambiguous lineage — rare cases lacking clear lineage commitment (undifferentiated) or expressing markers of more than one lineage (mixed phenotype, bilineal or biphenotypic); generally carries a poor prognosis with standard chemotherapy (Goldman-Cecil Medicine).

2. Pathogenesis

• Transcription factor disruption — gene rearrangements or point mutations that block normal differentiation along a lineage. Example: B-ALL frequently has mutations in PAX5, required for early B-cell differentiation (Robbins & Kumar, p. 402).
• Proliferation/survival-driving mutations — affecting tyrosine kinases and RAS pathways, complementing the differentiation block ("two-hit" concept in AML — a class I mutation driving proliferation plus a class II mutation blocking differentiation).
• Epigenetic/chromatin mutations — alterations in histone-modifying and chromatin-remodeling genes, increasingly recognized as important.
• Key recurrent lesions with prognostic/therapeutic significance:
  • BCR-ABL1 t(9;22) "Philadelphia chromosome" — found in ~25% of adult B-ALL, ~5% childhood B-ALL, and defines chronic myeloid leukemia; creates a constitutively active tyrosine kinase, targetable with TKIs.
  • PML-RARA t(15;17) — defines acute promyelocytic leukemia (APL); blocks myeloid differentiation at the promyelocytic stage; uniquely responsive to all-trans retinoic acid (ATRA), which overcomes the differentiation block pharmacologically.
  • NPM1 mutation, biallelic CEBPA mutation, FLT3-ITD — common AML molecular markers with major prognostic weight.
  • RUNX1-RUNX1T1 t(8;21), inv(16)/CBFB-MYH11 — "core binding factor" AML, generally favorable prognosis.
• Predisposing factors: antecedent MDS/myeloproliferative neoplasm, prior alkylating agent or topoisomerase-II-inhibitor chemotherapy (therapy-related AML, occurring 1-6 years post-exposure with characteristic cytogenetics — monosomy 5/7 and TP53 mutations with alkylators; 11q23/KMT2A rearrangements with topoisomerase II inhibitors), radiation, germline predisposition syndromes (Fanconi anemia, Down syndrome — GATA1-mutated AML in young children, Li-Fraumeni, GATA2 deficiency, RUNX1 familial platelet disorder) (Harrison's 22e, Ch. 109).

3. Classification

1. AML with defining genetic abnormalities (e.g., t(15;17)/PML-RARA, t(8;21)/RUNX1-RUNX1T1, inv(16)/CBFB-MYH11, NPM1-mutated, biallelic CEBPA-mutated, KMT2A-rearranged, etc.)
2. AML defined by differentiation (myelomonocytic, monoblastic, erythroid, megakaryoblastic, etc. — replacing the older FAB M0-M7 morphologic system)

4. Clinical Features

• Anemia → fatigue, pallor, dyspnea
• Thrombocytopenia → petechiae, ecchymoses, mucosal bleeding
• Neutropenia (despite often elevated total WBC from circulating blasts) → fever, infections

• Hepatosplenomegaly, lymphadenopathy (more common in ALL)
• Gingival hypertrophy, skin/leukemia cutis (especially monocytic AML)
• CNS involvement — headache, cranial nerve palsies (much more common in ALL; requires CSF evaluation and prophylaxis)
• Mediastinal mass — classic for T-ALL
• Bone pain (especially in children with ALL, from marrow expansion)
• DIC/bleeding — characteristic of APL, where blasts release procoagulant/thromboplastic material, causing life-threatening coagulopathy at presentation
• Constitutional symptoms — fever, weight loss, night sweats

5. Investigations

• CBC and peripheral blood film — cytopenias with circulating blasts; Auer rods (azurophilic cytoplasmic inclusions) are pathognomonic for myeloid lineage, especially prominent/numerous ("faggot cells") in APL.
• Bone marrow aspirate and biopsy — morphology, blast percentage, cellularity; mandatory for diagnosis.
• Immunophenotyping by flow cytometry — determines lineage (myeloid vs lymphoid vs mixed) and maturation stage; essential in every new case (Harrison's 22e, Table on pre-treatment workup).
• Cytogenetics (karyotype) and FISH — detects translocations/deletions defining subtype and risk group.
• Molecular studies/NGS panel — FLT3, NPM1, CEBPA, IDH1/2, TP53, KIT (AML); BCR-ABL1, Philadelphia-like signature (ALL).
• CSF examination — mandatory in ALL to assess CNS involvement before intrathecal prophylaxis.
• Coagulation studies (PT/aPTT, fibrinogen, D-dimer) — critical in suspected APL given DIC risk.
• Baseline organ function — renal/hepatic panel, uric acid/LDH (tumor lysis risk), echocardiogram or MUGA (baseline cardiac function before anthracyclines), HLA typing (for potential transplant), viral serologies, chest imaging (Harrison's 22e, Ch. 109, "Laboratory and Radiologic Studies").
• Cryopreservation of leukemic cells is often performed for future reference/research.

6. Prognosis

• Age — older age (>60) generally worse outcome in AML.
• WBC count at diagnosis — very high counts (hyperleukocytosis) worsen prognosis and raise leukostasis risk.
• Cytogenetics/molecular genetics — the dominant prognostic driver.
  • AML favorable: t(15;17), t(8;21), inv(16), NPM1-mutated without FLT3-ITD, biallelic CEBPA
  • AML adverse: complex karyotype, monosomy 5/7, TP53 mutation, FLT3-ITD (high allelic ratio), KMT2A rearrangement
  • ALL adverse: BCR-ABL1+ (though TKIs have improved this substantially), hypodiploidy, KMT2A-rearranged, Philadelphia-like signature, older age at diagnosis
• Response to induction / MRD status — failure to achieve remission after induction, or persistent MRD, strongly predicts relapse.
• Antecedent hematologic disease or therapy-related leukemia — worse prognosis.
• Mixed phenotype/ambiguous lineage leukemia — generally poor prognosis with standard chemotherapy.

7. Treatment

1. Induction — goal is to achieve complete remission (CR, <5% marrow blasts with count recovery).
   • AML: "7+3" regimen — an anthracycline (daunorubicin/idarubicin) for 3 days plus cytarabine for 7 days is classic; venetoclax + hypomethylating agent (azacitidine/decitabine) for older/unfit patients.
   • APL: ATRA plus arsenic trioxide (± anthracycline) — avoids cytotoxic induction in low/intermediate risk disease and dramatically improved cure rates; emergency treatment of DIC is critical.
   • ALL: multi-agent regimens (vincristine, corticosteroid, anthracycline, asparaginase ± cyclophosphamide); add a TKI (imatinib/dasatinib) for Philadelphia-positive ALL.
2. CNS-directed therapy — intrathecal chemotherapy (± cranial irradiation in select cases) is integral to ALL treatment given high CNS relapse risk; less routinely needed in AML except monocytic subtypes or CNS symptoms.
3. Consolidation/post-remission therapy — high-dose cytarabine cycles (AML) or continued multi-agent chemotherapy (ALL); goal is to eliminate residual disease and prevent relapse.
4. Maintenance — long-term, lower-intensity therapy (e.g., 6-mercaptopurine/methotrexate) is standard in ALL for 1-2+ years; less used in AML outside specific contexts.
5. Hematopoietic stem cell transplantation (allogeneic) — reserved for high-risk cytogenetics/molecular profile, relapsed/refractory disease, or failure to achieve remission after induction; it is the only curative option for roughly 30% of AML patients who don't achieve complete response after induction chemotherapy (Harrison's 22e, Ch. 110).
6. Targeted/novel agents — FLT3 inhibitors (midostaurin, gilteritinib) for FLT3-mutated AML, IDH1/2 inhibitors, venetoclax (BCL2 inhibitor) combinations, TKIs for Ph+ ALL, blinatumomab (bispecific CD19/CD3) and CAR-T cell therapy (CD19-directed) for relapsed/refractory B-ALL.
7. Supportive care — transfusion support, tumor lysis syndrome prophylaxis (hydration, allopurinol/rasburicase), antimicrobial prophylaxis during neutropenia (antibacterial, antifungal, antiviral as guided by risk), growth factor support (G-CSF) after chemotherapy.

8. Monitoring Treatment Response / Parameters for Improvement

• Serial CBC — recovery of neutrophil and platelet counts signals marrow recovery; persistent cytopenias may indicate residual disease or marrow aplasia.
• Repeat bone marrow examination post-induction (typically day 14 and at count recovery) — assesses blast clearance and morphologic remission (<5% blasts).
• Cytogenetic remission — disappearance of the baseline chromosomal abnormality; its reappearance signals relapse (Goldman-Cecil Medicine).
• Molecular remission / Minimal Residual Disease (MRD) — increasingly the most sensitive monitoring tool, assessed by multiparameter flow cytometry or PCR/NGS for known fusion transcripts or mutations (e.g., NPM1, BCR-ABL1 transcript levels). Persistent or rising MRD after therapy predicts relapse and may prompt treatment intensification or early transplant referral.
• Coagulation parameters — in APL, resolution of DIC (normalization of fibrinogen, D-dimer, PT/aPTT) is monitored closely during induction.
• Organ toxicity monitoring — renal/hepatic function, cardiac function (serial echocardiograms with anthracycline exposure), and vigilance for treatment complications (febrile neutropenia, typhlitis/neutropenic enterocolitis, tumor lysis syndrome, differentiation syndrome with ATRA/arsenic).
• Post-transplant monitoring (if HSCT performed) — chimerism studies, surveillance for graft-versus-host disease, CMV PCR monitoring, and continued MRD assessment.

Acute Leukemia — Full Detailed Note

1. Basics

• AML — myeloid lineage; median age ~65 years; the most common acute leukemia in adults (Washington Manual of Medical Therapeutics, p. 3307).
• ALL — lymphoid lineage (B-lineage ~75%, T-lineage ~25%); peak incidence age 2-10 for B-ALL; T-ALL more common in adolescence, often with a mediastinal mass (Robbins & Kumar Basic Pathology, p. 402).
• Acute leukemia of ambiguous lineage — undifferentiated or mixed-phenotype (bilineal/biphenotypic) blasts; poor prognosis with standard chemotherapy (Goldman-Cecil Medicine).

2. Pathogenesis

• Differentiation block — mutations/rearrangements disabling transcription factors that drive normal lineage maturation (e.g., PAX5 mutations in B-ALL block early B-cell differentiation).
• Proliferation/survival drive — complementary mutations in tyrosine kinases, RAS pathway genes — the "two-hit" model for AML (a proliferation-driving lesion plus a differentiation-blocking lesion).
• Epigenetic dysregulation — mutations in chromatin/histone-modifying genes.
• Key recurrent lesions:
  • BCR-ABL1 t(9;22) "Philadelphia chromosome" — ~25% of adult B-ALL, ~5% pediatric B-ALL; constitutively active tyrosine kinase; targetable with TKIs.
  • PML-RARA t(15;17) — defines APL; blocks differentiation at the promyelocytic stage; uniquely reversible with ATRA.
  • NPM1 mutation, biallelic CEBPA, FLT3-ITD — major AML prognostic/molecular markers.
  • RUNX1-RUNX1T1 t(8;21), inv(16)/CBFB-MYH11 — "core binding factor" AML, generally favorable.
  • KIT mutation testing is recommended at diagnosis but per ELN/NCCN is not used for risk stratification; MRD status is used instead (Henry's Clinical Diagnosis, 9780323673204_block38).
• Predisposing factors: antecedent MDS/MPN, prior chemotherapy (alkylator-related AML at 4-6 years post-exposure with monosomy 5/7, TP53 mutation, poor prognosis; topoisomerase-II-inhibitor-related AML at 1-3 years with 11q23/KMT2A rearrangement and monocytic features), radiation, germline syndromes (Down syndrome with GATA1-mutated megakaryoblastic AML in young children, Fanconi anemia, Bloom syndrome, ataxia-telangiectasia, GATA2 deficiency, congenital neutropenia/Kostmann syndrome, RUNX1 familial platelet disorder) (Harrison's 22e, Ch. 109).

3. Classification

1. AML with defining genetic abnormalities (t(15;17)/PML-RARA, t(8;21)/RUNX1-RUNX1T1, inv(16)/CBFB-MYH11, mutated NPM1, biallelic CEBPA, KMT2A-rearranged, NUP98-rearranged, etc.)
2. AML defined by differentiation (replacing the old FAB M0-M7 morphologic scheme)

• B-ALL: pro-B (CD19/CD22+, CD10-, ~10%), common/CALLA+ (CD10+, ~50-60%, best outcomes), pre-B (cytoplasmic Ig+, ~10%), mature B (surface Ig+, <5%)
• T-ALL: early T-precursor (CD7+, CD1a-, CD3-), thymic (CD1a+), mature (surface CD3+)

4. Clinical Features

• Anemia → fatigue, pallor, dyspnea
• Thrombocytopenia → petechiae, ecchymoses, mucosal bleeding
• Neutropenia (despite high total WBC from circulating blasts) → fever, infection

• Hepatosplenomegaly, lymphadenopathy (more prominent in ALL)
• Gingival hypertrophy, leukemia cutis (monocytic AML)
• CNS involvement — headache, cranial neuropathies (much more frequent in ALL)
• Mediastinal mass — classic for T-ALL
• Bone pain — common presenting symptom in pediatric ALL
• DIC/coagulopathy — hallmark of APL from release of procoagulant material by blasts; can cause fatal hemorrhage (especially intracranial) at presentation
• Constitutional symptoms — fever, night sweats, weight loss

5. Investigations

• CBC + peripheral smear — cytopenias with circulating blasts; Auer rods (myeloid lineage, especially numerous "faggot cells" in APL)
• Bone marrow aspirate + biopsy — mandatory for diagnosis; morphology and blast quantification
• Flow cytometry immunophenotyping — lineage assignment, maturation stage — required in every new case
• Cytogenetics (karyotype) + FISH — defines subtype and risk group
• Molecular/NGS panel — FLT3, NPM1, CEBPA, IDH1/2, TP53, KIT (AML); BCR-ABL1, Ph-like signature (ALL)
• CSF examination — mandatory in ALL before intrathecal prophylaxis
• Coagulation studies (PT/aPTT, fibrinogen, D-dimer) — critical if APL suspected
• Baseline organ workup — renal/hepatic panel, uric acid/LDH/phosphate/potassium (tumor lysis risk), echocardiogram/MUGA (pre-anthracycline), HLA typing (transplant candidacy), viral serologies, chest imaging (Harrison's 22e, "Laboratory and Radiologic Studies," pre-treatment workup table)
• Cryopreservation of leukemic cells often performed for future study/relapse comparison

6. Prognosis

• Favorable: t(15;17)/PML-RARA, t(8;21)/RUNX1-RUNX1T1, inv(16)/CBFB-MYH11, mutated NPM1 without FLT3-ITD, biallelic CEBPA
• Intermediate: normal karyotype without adverse markers, t(9;11), mutated NPM1 with FLT3-ITD, other non-defined abnormalities
• Adverse: complex karyotype, monosomy 5/7 or del(5q)/del(7q), TP53 mutation, KMT2A-rearranged, FLT3-ITD (high allelic ratio) without NPM1 mutation, myelodysplasia-related mutations

7. Treatment

• Induction: "7+3" (anthracycline x3 days + cytarabine x7 days) for fit patients; venetoclax + hypomethylating agent (azacitidine/decitabine) for older/unfit patients — recent systematic reviews/meta-analyses (2024-2025) confirm improved complete response rates with venetoclax-HMA combinations in elderly AML, though with increased cytopenias (PMIDs 38497866, 38703055, 40287739).
• Consolidation: high-dose cytarabine cycles.
• Targeted agents: FLT3 inhibitors (midostaurin, gilteritinib), IDH1/2 inhibitors, venetoclax combinations.
• Allogeneic HSCT: reserved for intermediate/adverse-risk disease, MRD-positive remission, or relapsed/refractory disease; cures ~30% of patients who fail to achieve remission after induction — the only curative option in that setting (Harrison's 22e, Ch. 110).

• ATRA + arsenic trioxide (chemotherapy-free) for low/intermediate-risk (WBC ≤10×10⁹/L); addition of an anthracycline for high-risk (WBC >10×10⁹/L) (Washington Manual, p. 3381-3382).
• ATRA reduces DIC risk but can precipitate differentiation (retinoic acid) syndrome — fever, weight gain, dyspnea, pulmonary infiltrates, pleural/pericardial effusions, hypotension, renal failure — occurring within the first 3 weeks; treated/prevented with dexamethasone and, if severe, temporary ATRA/ATO interruption plus hydroxyurea for cytoreduction (Harrison's 22e; Goodman & Gilman's Pharmacology).

• Induction: vincristine, corticosteroid, anthracycline, asparaginase ± cyclophosphamide; add a TKI (imatinib/dasatinib) for Ph+ ALL.
• Three-phase structure: induction → post-remission therapy → CNS prophylaxis (Goldman-Cecil, "Treatment of Acute Lymphoblastic Leukemia").
• CNS prophylaxis — intrathecal chemotherapy ± high-dose methotrexate ± cranial irradiation; combined-modality prophylaxis has reduced CNS relapse to 2-5%. Note: not all TKIs cross the blood-brain barrier equally (imatinib penetrates poorly), which affects CNS-directed strategy in Ph+ ALL (Harrison's 22e).
• Maintenance: prolonged low-intensity therapy (6-mercaptopurine/methotrexate) for 1-2+ years — a defining feature distinguishing ALL treatment from AML.
• Relapsed/refractory B-ALL: blinatumomab (CD19/CD3 bispecific) and CD19-directed CAR-T cell therapy. Recent meta-analyses (2024-2025) show CAR-T and blinatumomab both produce meaningful remission rates in relapsed/refractory B-ALL, with ongoing work identifying biomarkers (e.g., MRD depth, cytokine release syndrome severity) predicting durable response (PMIDs 41181124, 38135295, 39956997) — comparative data suggest CAR-T achieves higher remission rates than blinatumomab but with more toxicity (cytokine release syndrome, neurotoxicity); MRD-negative status after either therapy is the strongest predictor of durable remission.

• Tumor lysis syndrome prevention — aggressive IV hydration, allopurinol, and rasburicase (recombinant urate oxidase) for high-risk patients (high tumor burden, high WBC); rasburicase has strong trial evidence for both prevention and treatment of hyperuricemia in TLS (Brenner & Rector's The Kidney; multiple phase III trials cited).
• Antimicrobial prophylaxis during neutropenia, transfusion support, growth factor (G-CSF) support after chemotherapy.

8. Monitoring Treatment Response / Parameters for Improvement

• Serial CBC — count recovery signals marrow regeneration; persistent cytopenia raises concern for residual disease or aplasia.
• Repeat bone marrow exam (typically day 14 and at count recovery) — confirms morphologic complete remission (<5% blasts).
• Cytogenetic remission — disappearance of the baseline abnormality; reappearance signals relapse.
• Minimal/Measurable Residual Disease (MRD) — the most sensitive modern monitoring tool. Methods: multiparameter flow cytometry (detecting leukemia-associated aberrant immunophenotypes), RT-PCR for fusion transcripts (e.g., BCR-ABL1, PML-RARA), and increasingly NGS-based mutation tracking (e.g., NPM1) (Harrison's 22e, "Minimal Residual Disease" section; Henry's Clinical Diagnosis). MRD-negative status after induction/consolidation is now central to risk-adapted decisions, including whether to proceed to allogeneic transplant.
• Coagulation parameters — in APL, resolution of DIC (normalizing fibrinogen, D-dimer, PT/aPTT) is tracked closely during induction.
• Organ toxicity surveillance — renal/hepatic panels, serial echocardiograms with anthracycline exposure, vigilance for febrile neutropenia, typhlitis, tumor lysis syndrome, and (in APL) differentiation syndrome.
• Post-HSCT monitoring (if transplanted) — donor chimerism studies, GVHD surveillance, CMV PCR monitoring (with letermovir prophylaxis or preemptive ganciclovir/foscarnet strategies), continued MRD assessment.

Evidence currency check

• Venetoclax + hypomethylating agents show improved response in elderly/unfit AML but with more thrombocytopenia (PMID 38497866, 38703055, 40287739) - consistent with current use in unfit patients described above.
• CAR-T and blinatumomab remain effective for relapsed/refractory B-ALL, with MRD depth and cytokine release syndrome severity emerging as outcome predictors (PMID 41181124, 38135295, 39956997) - this refines but does not contradict standard textbook positioning of these agents.

Acute Lymphoblastic Leukemia (ALL)

1. Causes / Risk Factors

2. Pathogenesis

• Differentiation block - mutation/deletion of transcription factors essential for lymphoid maturation. In B-ALL, the pan-B lineage marker CD19 and transcription factor PAX5 are characteristically expressed on the malignant clone, and PAX5 itself is frequently mutated/deleted, arresting cells at an early B-progenitor stage (Robbins, Cotran & Kumar Pathologic Basis of Disease, "Morphology").
• EBF1 - another transcription factor essential for B-cell development; deletions found in B-ALL blasts (Firestein & Kelley's Textbook of Rheumatology).
• Proliferation drive - complementary signaling mutations (RAS, FLT3, JAK1/3) seen particularly in early T-cell precursor (ETP) ALL, along with epigenetic modifier mutations (EZH2, SUZ12) (Henry's Clinical Diagnosis, "Lymphoblastic leukemia/lymphoma: risk stratification and MRD").
• Chromosomal translocations create fusion oncoproteins that are themselves aberrant transcription factors or kinases (see table below) - these are acquired, non-random, and disappear in remission, reappearing at relapse.
• Clonal evolution - additional subclonal mutations accumulate over time, contributing to relapse and treatment resistance.

3. Gene / Transcription Factor Abnormalities in ALL

4. Prognosis - Risk Stratification Table

5. Management and Follow-up

1. Induction - vincristine, corticosteroid (prednisone/dexamethasone), an anthracycline, and asparaginase, ± cyclophosphamide. Ph+ ALL adds a TKI (imatinib/dasatinib) from day 1. Goal: complete morphologic remission (<5% marrow blasts, count recovery).
2. Post-remission (consolidation) therapy - cytarabine/high-dose methotrexate-based regimens, often modeled on AML-type intensification blocks; reduces relapse risk.
3. CNS prophylaxis - intrathecal chemotherapy (methotrexate ± cytarabine ± hydrocortisone) ± high-dose systemic methotrexate ± cranial irradiation (reserved for higher-risk cases). Combined-modality prophylaxis has cut CNS relapse rates to 2-5%. Important caveat: not all TKIs cross the blood-brain barrier equally (imatinib penetrates poorly), so CNS strategy must be individualized in Ph+ ALL (Harrison's 22e).
4. Maintenance therapy - prolonged (1-2+ years) lower-intensity therapy, typically oral 6-mercaptopurine and methotrexate with periodic vincristine/steroid pulses - a defining feature that distinguishes ALL treatment duration from AML.
5. Relapsed/refractory disease - blinatumomab (CD19/CD3 bispecific antibody) or CD19-directed CAR-T cell therapy for B-ALL; allogeneic hematopoietic stem cell transplant considered for high-risk cytogenetics, poor MRD response, or relapse.

6. Recommended Home Measures Including Diet

• Practice strict hand hygiene; avoid crowded places and people who are visibly sick.
• Avoid live vaccines during active treatment (household members should also avoid live oral polio and similar live vaccines when possible).
• Good oral hygiene with a soft toothbrush to reduce mucositis-related infection risk; avoid dental procedures without hematology clearance.
• Monitor temperature at home; any fever (typically ≥38°C/100.4°F) during neutropenia is an emergency requiring immediate medical contact - do not wait it out at home.
• Avoid contact with pet feces/litter boxes, standing water, or gardening/soil without gloves during neutropenia (reduces fungal/bacterial exposure).

• Ensure all meat, poultry, eggs, and seafood are thoroughly cooked (avoid raw/undercooked sushi, rare meat, soft-boiled eggs).
• Wash fruits and vegetables thoroughly; some centers advise avoiding unwashed raw produce, especially salad greens/sprouts, during severe neutropenia - follow the treating center's specific guidance since practices vary.
• Avoid unpasteurized dairy products, juices, and honey.
• Avoid moldy or aged cheeses and food past expiry.
• Maintain adequate hydration, especially around chemotherapy cycles, to support kidney clearance and reduce tumor lysis/uric acid risk.
• Small, frequent, high-protein, high-calorie meals help offset nutritional losses from mucositis, nausea, and taste changes; a dietitian referral is often useful for patients struggling to eat during treatment.
• Avoid grapefruit and grapefruit juice if on certain chemotherapy agents/TKIs due to drug interaction potential (check with the treating oncology team for specific drug-food interactions).

• Bruising/bleeding precautions - use a soft toothbrush, avoid contact sports, use caution with razors, avoid NSAIDs/aspirin (can worsen bleeding risk from thrombocytopenia) unless specifically approved.
• Rest balanced with light activity as tolerated; fatigue from anemia is common.
• Keep a symptom diary and maintain close contact with the treatment team - do not self-manage fever, bleeding, or worsening fatigue at home.
• Psychosocial support - especially important for children and families; connect with hospital social work/psycho-oncology services.
• Avoid alcohol and smoking, which can worsen mucositis and interact with medications.

Prognostic Interpretation: KRAS + NRAS + PTPN11 + CDKN2A + CDKN2B Positive

Evidence for each component

Combined interpretation

• RAS pathway mutations (KRAS/NRAS/PTPN11) are classic drivers of relapse biology in ALL - they are frequently detected as minor subclones at diagnosis that are selected for and expand under treatment pressure, explaining why patients can have reassuring early MRD results yet still relapse.
• CDKN2A/CDKN2B co-deletion removes key cell-cycle checkpoint control (p16/INK4A, p14/ARF, p15/INK4B), independently driving poor response to induction (worse prednisolone response) and higher relapse risk.
• Having both classes of alteration together stacks risk rather than cancelling out - this is not a scenario described in guidelines as favorable under any standard risk stratification (ETV6-RUNX1, hyperdiploidy, etc.), and is more consistent with an adverse/high-risk category, particularly if this occurs in the context of Ph-like or T-ALL/ETP-ALL biology, where RAS pathway and CDKN2A/2B lesions co-occur frequently.

Practical implications

• This patient should be treated as high-risk, regardless of favorable early findings elsewhere (e.g., good initial MRD clearance), because RAS-pathway-positive relapse can occur even after an apparently good early response.
• Closer/serial MRD monitoring (not just single post-induction check) is warranted given the known subclonal-expansion relapse mechanism.
• Consider earlier discussion of treatment intensification or allogeneic transplant referral if this profile occurs alongside other high-risk features (poor early response, high presenting WBC, adverse immunophenotype).
• RAS pathway mutations are potentially druggable - preclinical/early clinical data show RAS-pathway-mutant relapsed ALL cells are sensitive to MEK inhibition (e.g., selumetinib, trametinib) (PMID 25253770); this may be relevant if relapse occurs or in a clinical trial setting.
• If this profile appears in a young child with syndromic features (short stature, congenital heart disease, characteristic facies), consider whether an underlying germline RASopathy (Noonan syndrome, PTPN11/KRAS/NRAS germline) is present, since these predispose to leukemia (more classically JMML, but also reported with ALL) - germline testing/genetics referral would be reasonable in that context.